MOS — The Mosaic Company

As of 2026-08-27, the Street is cautious: consensus is Hold, the average analyst target is $26.44 (roughly 11% above the $23.76 price), and Q2 2026 adjusted EPS of $0.13 barely beat the $0.12 estimate while revenue missed badly and dropped 6% YoY. GAAP losses and margin compression keep sentiment neutral-to-defensive despite the refinancing and asset-sale progress.

Revenue has been choppy rather than collapsing: TTM revenue is roughly $11.88B, and Q2 2026 revenue of $2.82B was down 6% YoY from $3.01B. The clear deterioration is in profitability: TTM gross margin is 11.5%, operating margin 1.4%, and net margin 0.4%, with Q1/Q2 2026 operating income at -$372.9M and -$35.5M due to charges and high costs. Underlying operations are less bad than GAAP suggests—Q2 adjusted EPS was positive—but the trend is still down from 2025's stronger quarters, and free cash flow has been negative for the last four straight quarters.

At the $23.76 price as of 2026-08-27, the TTM P/E of 118.8x is essentially meaningless because earnings are near zero. P/B is 0.66x and P/S is 0.64x, below the 5-year average P/S of 0.84x, so the stock looks cheap on assets and sales. However, on the consensus forward EPS estimate of $0.606, the forward P/E is roughly 39x, which is not cheap—valuation is neutral until earnings actually normalize, not a clear bargain.

As of 2026-08-27, the $23.76 price implies the market is capitalizing roughly $1.44 of normal EPS at Mosaic's 5-year average P/E of 16.5x. Analysts' next-FY EPS of $0.606 is far below that, so the market is clearly looking through the current trough toward a 2027-2028 recovery. If normalized earnings reach only ~$1.50, the stock is fairly priced; if the recovery is slower or margins stay at current levels, earnings support breaks down and valuation rests on book value and dividend alone.

As of 2026-08-27, RSI is 56.8—neither oversold nor overbought. Price is 3.8% above the 20-day SMA and 6.3% above the 50-day SMA, but still 3.2% below the 200-day SMA. This is a short-term bounce inside a longer-term downtrend/range; there is no oversold reversion signal, so the technical read does not argue for immediate entry.

• Global fertilizer prices remain well below the 2022 boom levels; Mosaic is a price-taker in potash and phosphates.
• Elevated input costs—especially sulfur and ammonia—are squeezing phosphate margins at the worst point in the cycle.
• Trade frictions between the U.S. and Canada, Chinese export quotas, and Middle East shipping disruptions create supply-chain and regulatory uncertainty.
• High fixed-cost base and heavy capex have produced four consecutive quarters of negative free cash flow, increasing reliance on financing and asset sales.
• Farmer economics are weak, with low grain/crop prices discouraging fertilizer application volume and limiting pricing power.

• Q3 2026 earnings in late October/early November—any sign of volume recovery, working-capital cash inflow, or lower capex could improve sentiment.
• Progress on asset sales (Carlsbad, Taquari-Vassouras) that would bring in cash and simplify the portfolio.
• A fertilizer price rebound or a drop in sulfur/ammonia input costs would directly expand Mosaic's thin margins.
• The September 10, 2026 ex-dividend date and September 24, 2026 payment confirm the $0.22 quarterly dividend remains intact for now.

• Prolonged fertilizer downturn could keep operating margins near zero and turn the already-negative FCF into a liquidity problem.
• Cash and equivalents of $294M look thin next to $4.06B of current liabilities; the current ratio of 1.34 is adequate, but negative FCF makes the cushion less comfortable.
• Further impairments or write-downs, particularly around Brazil and idled assets, could reset book value lower.
• Asset divestitures may deliver lower-than-book proceeds, and execution risk is real.
• The 4% dividend is a support factor, but it is not guaranteed if cash flow stays negative for an extended period.

Mosaic is a deep cyclical currently on the wrong side of the fertilizer cycle. The stock is cheap on book value and sales, and the refinancing/asset sales reduce near-term solvency risk, but current profitability and free cash flow are genuinely poor. I would not be a buyer until there is tangible evidence that margins and cash conversion are turning; this is a watchlist/option-like turnaround, not a compounder.

I applied Mosaic's 5-year average P/E of 16.5x to a conservative normalized EPS estimate of ~$1.50—well below the last strong year's ~$3.90 run-rate but above the trough/2027 consensus of ~$0.60—which yields $24.75. This is also consistent with the stock's ~0.66x price-to-book and sits modestly below the consensus analyst target rather than just repeating it.